Characteristic of CD4+CD25+ T Cells in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate with Different BCR-ABL Transcripts Levels Response
Keywords:CML, Imatinib mesylate, CD4 CD25 Tregs, PD1.
Background: Several clinical trials on cancer showed a correlation between elevated levels of regulatory
T cells with either poor prognosis or poor response to some therapies. Hence, in this study we tried to
measure the regulatory T cells (CD4+CD245+) count and to evaluate the program death receptor 1(PD1)
as a one of the main suppressive mechanisms that regulatory T cells use in CML patients with different
molecular response to imatinib therapy. Method: Flow cytometry technique was used to analyze 30 sample
of optimal molecular response of CML patients (BCR-ABL transcripts ? 0.1%) and 30 sample of failure
molecular response patients (BCR-ABL transcripts >1%) with or without hematological failure, in order to
assess the CD4+CD25+ T cells (Tregs) and PD1 expression on these cells. Thirty samples age and gender
matched were used as healthy controls. Results: A high proportion of CD4+CD25+ T cells was found in
failure groups compared to control and optimal groups(P= <0.001), while there was no significant difference
between control and optimal groups with (P= 0.481). A cutoff value of CD4+CD25+ T cells at >33.7 % was
highly significant with high sensitivity and specificity. This value can be used to determine the failure from
the optimal CML responders. There was no noticeable differences (P= 0.125) in PD1+ expression among
CD4+CD25+ T cells. Conclusion: A high percentage of Treg cells in the failure CML group might be an
indication of immune escape of leukemic cells in those patients compared to the other investigated groups.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.